BioCorRx President Brady Granier resigns; Louis Lucido appointed as President

BioCorRx Inc.

Brady Granier resigned as President of BioCorRx and CEO of BioCorRx Pharmaceuticals, effective Jan 31, 2024; remains on board.
Louis Lucido appointed Interim President from Jan 5, 2024, then President from Feb 1, 2024; remains board member.
Lucido to receive $200,000 annual compensation paid in equity monthly (~$16,667 in shares based on 3-day avg closing price).
Lucido, 75, formerly COO of DoubleLine Group and founding partner; director since March 2019.
Granier's resignation not due to any disagreement with the company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Louis Lucido

President

BICX · BioCorRx Inc.

Effective: 2024-02-01
Filed: January 5, 2024, 6:59 PM ET

On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024

Departed

Brady Granier

President

BICX · BioCorRx Inc.

Effective: 2024-01-31
Successor: Louis Lucido
Filed: January 5, 2024, 6:59 PM ET

On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. (the “ Company ”) and Chief Executive Officer of BioCorRx Pharmaceuticals, a subsidiary of the Company, effective January 31, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Louis Lucido was appointed as President at BioCorRx Inc..

Action: appointed
Role: President

Exact text from the filing

On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brady Granier resigned as President at BioCorRx Inc..

Action: resigned
Role: President

Exact text from the filing

On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. (the “ Company ”) and Chief Executive Officer of BioCorRx Pharmaceuticals, a subsidiary of the Company, effective January 31, 2024

View on SEC.gov

BioCorRx Inc. filing history →

Source: SEC EDGAR

accession 0001477932-24-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.